Navigation Links
Compound in Medical Technology

MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes

... study evaluating teplizumab, an investigational compound under development for the treatment of ... Teplizumab Teplizumab, an investigational compound under development for the treatment of ... about the potential of the investigational compound teplizumab for the treatment of type 1 diabetes ...

Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial

... TZDs that led us to develop this lead compound and our drug portfolio. These results further ... and Drug Administration for a second-generation compound by the end of 2009. Nearly 100 patients ... Company. "We are pleased that our lead compound performed so well in the Phase IIa study," said ...

New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel

... about the potential of the invest i gational compound prasugrel (CS-747, LY640315) and reflects Daiichi ... beliefs. However, as with any pharmaceutical compound under development, there are su b stantial ... review. There is no guarantee that the compound will receive regulatory approval, that the ...

NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds

... or enhance the biological activity of the natural compound while adding pharmaceutically acceptable ... the ear during 2009 with NovaBay's lead Aganocide compound NVC-422. Professors Nagl and Gottardi have also ... clinical opportunities provided by our Aganocide compound platform." "We expect to substantially ...

Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study

... that the investigational antiplatelet compound met its primary endpoints of safety and ... was to assess whether patients treated with the compound in addition to standard-of-care therapies had ... thromboxane or ADP pathways. Specifically, this compound is being investigated as an oral antiplatelet ...

ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410

... reverse transcriptase inhibitor (NNRTI). The compound possesses a second mechanism of action which ... approved RT and protease inhibitors. The compound is well suited for use as a component of primary ... studies have also demonstrated the ability of the compound to be used in combination with all other approved ...

Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin

... - Fluoroquinolone compound Demonstrates Potent Activity Against Antibiotic ... delafloxacin was shown to be the more active compound overall, including its activity against ... continues to show that this broad spectrum compound is likely to be a valuable tool in the ...

Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application

... about the potential of the investigational compound prasugrel (CS-747, LY640315) and reflects Daiichi ... beliefs. However, as with any pharmaceutical compound under development, there are substantial ... regulatory review. There is no guarantee that the compound will receive regulatory approval, that the ...

In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop

... opportunity to further evaluate Taligen's TT30 compound in our research activities has been invaluable in ... the autoimmune response in vivo. No other type of compound has this dual profile of activity. I also believe ... pathway using TT30 as an immunomodulatory compound for treating complement-mediated diseases In ...

deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders

... the US Food and Drug Administration (FDA). The compound is being developed as a new and potentially safer ... a wide margin for safety and tolerability. The compound has the potential to eliminate the nausea that ... of DG071 with a strategic partner. "This compound has exciting therapeutic potential and reflects ...

Pharmaleads' Lead Candidate for Pain, PL37, Enters Phase I

... dose Phase I study with PL37, its lead compound for oral treatment of neuropathic pain. ... estimated to reach 5 billion USD by 2010. This compound originates from the work of Pharmaleads' ... CEO of Pharmaleads, "PL37 is Pharmaleads' first compound to enter clinical development and the ...

Quigley Anti-Viral Compound QR448(a) Successfully Prevents Transmission of Infectious Bronchitis in Chickens

... examine the ability of its veterinary anti-viral compound QR448(a) to prevent the transmission ... results have also demonstrated that the QR448(a) compound can effectively be applied to a larger population ... and suitable for mass delivery of the compound to thousands of commercial birds." About the ...

Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate

... Vitro Metabolism of Liquiritigenin, a Bioactive compound Isolated from the Chinese Herbal Selective ... is three times more potent than the parent compound towards selective activation of the estrogen ... study shows that the metabolism of a major active compound of MF101 will most likely not adversely ...

Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel

... about the potential of the investigational compound prasugrel (CS-747, LY640315) and reflects Daiichi ... beliefs. However, as with any pharmaceutical compound under development, there are substantial ... regulatory review. There is no guarantee that the compound will receive regulatory approval, that the ...

Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel

... about the potential of the investigational compound prasugrel (CS-747, LY640315) and reflects Daiichi ... beliefs. However, as with any pharmaceutical compound under development, there are substantial ... regulatory review. There is no guarantee that the compound will receive regulatory approval, that the ...

Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events

... about the potential of the investigational compound prasugrel (CS-747, LY640315) and reflects Daiichi ... beliefs. However, as with any pharmaceutical compound under development, there are substantial ... regulatory review. There is no guarantee that the compound will receive regulatory approval, that the ...

Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.

... and, if approved, market and distribute the compound worldwide. In a simultaneous transaction, ... are extremely pleased to be able to license this compound from Merck for further development ... with Diakron for the development of this Merck compound is a significant development in Orchid's drug ...

Anavex presents neuroprotective effects of Anavex 1-41 at the International Conference on Alzheimer's Disease 2008

... 2008, Chicago, USA, July 26 to 31, 2008. The compound has a synergistic neuroprotective and ... Neuroprotection was attained in the ANAVEX 1-41 compound at very low doses (0,1mg/kg) in mice. At the same ... relief from Alzheimer's disease. Moreover, the compound does not target pathologoanatomic hallmarks, such ...

Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation

... the company was abandoning development of the compound for Alzheimer's disease. "While the results of ... PBT2 is a metal-protein attenuating compound (MPAC) being developed by Prana Biotechnology as ... efficacy of two different doses of the compound in patients with early Alzheimer's. This was done ...

Phase III Data Show Vanda Pharmaceuticals' Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia

... utility of tasimelteon and the ability of the compound to treat sleep disorders over a period of four ... (average of Nights 22 and 29) use of the compound as well as measures of sleep duration (Total ... Vanda's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia for which ...

FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel

... about the potential of the investigational compound prasugrel (CS-747, LY640315) and reflects Daiichi ... beliefs. However, as with any pharmaceutical compound under development, there are substantial ... regulatory review. There is no guarantee that the compound will receive regulatory approval, that the ...

HUYA Bioscience Int'l Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China

... sulphate), a promising anti-arrhythmic compound sourced from China. The Agency reviewed and ... of HBI-3000 was well tolerated. The compound has also been tested in an intravenous (IV) ... strategic offices in China, the broadest Chinese compound portfolio, and more exclusive agreements with ...

ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease

... to enable first-in-human studies on this compound in the second half of the year. Structurally ... Executive Officer of ChemoCentryx. "This new compound adds to our existing clinical pipeline that ... forms of IBD. In preclinical studies, the compound worked both therapeutically and prophylactically ...

ViroDefense Inc Announces Selection of Poliovirus Antiviral Preclinical Candidate

... compound Emerged from Technology Licensed from ... today announced that it has chosen to advance a compound licensed to ViroDefense Inc by Schering-Plough ... exclusive rights for development of a specific compound series for polio indications. The license was ...

Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization

... anti-viral activity of its compound QR448(a). The compound was administered to chicks that had been ... in chickens have demonstrated that our QR448(a) compound can prevent as well as treat 2 week old SPF ... new animal drug number or allow this compound to be marketed for IBV. Furthermore, no claim is ...

Exelixis Announces First Quarter 2008 Financial Results

... its option to develop and commercialize our compound XL518, a selective and potent inhibitor of MEK, ... in a phase 1 clinical trial. Selection of the compound and opt-in by Genentech triggered a payment ... its option to develop and commercialize our compound XL139, an inhibitor of the hedgehog signaling ...

Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome

... a sustained-release investigational compound to treat Restless Legs Syndrome (RLS), showed ... of Neurology (AAN). The investigational compound is being developed by XenoPort (Nasdaq: XNPT ) and GlaxoSmithKline (NYSE: GSK ). "This novel compound is the first non-dopaminergic agent to ...

HUYA Bioscience Int'l Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound

... with the U.S. FDA for a development-stage compound sourced from China. The new compound, HBI-8000 ... development and commercialization rights to the compound worldwide outside of China, while ... strategic offices in China, the broadest Chinese compound portfolio, and more exclusive agreements with ...

Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007

... "We believe ITI-007 represents a unique compound that may have broad use in treating ... About ITI-007 ITI-007 is an orally available compound which combines potent 5HT2A receptor antagonism ... Additionally, its profile suggests the compound may be appropriate for the treatment of sleep ...

Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722

... "We believe ITI-007 represents a unique compound that may have broad use in treating ... About ITI-007 ITI-007 is an orally available compound which combines potent 5HT2A receptor antagonism ... Additionally, its profile suggests the compound may be appropriate for the treatment of sleep ...

Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach

... Pfizer through Quark's license to Pfizer of the compound RTP-801i-14 for the treatment of Age-related ... (AMD) and a number of other indications. This compound entered the clinic in early 2007. Silence ... to the AtuRNAi structure for its proprietary compound AKIi-5. This compound is in a Phase I human ...

Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel

... about the potential of the investigational compound prasugrel (CS-747, LY640315) and reflects Daiichi ... beliefs. However, as with any pharmaceutical compound under development, there are substantial ... regulatory review. There is no guarantee that the compound will receive regulatory approval, that the ...

Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative Disorders

... said, "We are highly encouraged by Cytopia's compound in this model of myeloproliferative disease which ... this animal model augers well for activity of the compound in the clinic." The compound will now be progressed into formal preclinical ...

Anti-Cancer Drug CYT997 Update

... will investigate the activity of this anti-cancer compound in specific cancer types with high unmet medical ... activity. The potential activity of this compound in multiple myeloma extends the utility of the ... approval and a fast-to-market strategy for the compound in this cancer indication. It is anticipated ...

HUYA Bioscience Int'l Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile

... CEO of HUYA, "the progress on this exciting new compound validates the efficiency and effectiveness of our ... that of smaller competitors with "one-off" single compound strategies. With three strategic offices in China, the broadest Chinese compound portfolio, and more exclusive agreements with ...

FDA Grants Priority Review for PROMACTA(R) (eltrombopag)

... a decision on the NDA for the investigational compound within six months of the submission. In ... where it will be marketed as REVOLADE(R). The compound is also being studied for long-term treatment of ... is an investigational compound that has not received regulatory approval in any ...

Genetic Variation Associated with Treatment Response in a Clinical Study of a New Atypical Antipsychotic Fiaptatm (iloperidone)

... has recently submitted an NDA to the FDA, is a compound for the treatment of schizophrenia. Vanda's second product candidate, VEC-162, is a compound for the treatment of sleep and mood disorders, ... Vanda's third product candidate, VSF-173, is a compound for the treatment of excessive sleepiness in ...

NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference

... novel, radicicol-based Hsp90 inhibitors in its compound series. NXD30001 demonstrated efficacy in ... in Phase 2 clinical trials for cancer. The compound series appears to bind Hsp90 in a different mode ... via intraperitoneal (i.p.) dosing and that the compound accumulates in tumors at above ...

FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel

... about the potential of the investigational compound prasugrel (CS-747, LY640315) and reflects Daiichi ... beliefs. However, as with any pharmaceutical compound under development, there are substantial ... regulatory review. There is no guarantee that the compound will receive regulatory approval, that the ...

Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development

... of PS031291 as a preclinical development compound from its internal CCR1 discovery program. ... intends to initiate GLP toxicology studies on the compound in the current quarter. "PS031291 strengthens ... its various collaborators, PS031291 is the first compound to emerge from Pharmacopeia's internal drug ...
Other Contents
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 16, 2014 ... has licensed its PerformTek biometric technology to industry leaders ... their highly accurate, clinically validated, biometric wearable products. These ... January 6-9 in Las Vegas . ... the technology is accurate, flexible and robust – with ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... their offering. One major trend ... multimodal biometric systems. Multimodal biometric systems utilize more ... and identification purposes. This helps to reduce the ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Wake Forest Baptist ... education building for its School of Medicine. Funding for ... larger capital campaign that will be publicly launched next ... be located in the former 60 series R.J. Reynolds ... Innovation Quarter. Construction will begin immediately with plans to ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
(Date:12/25/2014)... York, New York (PRWEB) December 25, 2014 ... the 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) ... LLP reports. According to an Order issued in the ... 20th, the Court will convene an open conference on ... Building and United States Courthouse in West Palm Beach, ...
(Date:12/25/2014)... “Every three months the trends for ... evening dress will be one of the hottest styles in ... says. Today, the company releases 26 A-line sweetheart evening dresses, ... off. , “We are trying our best to help ... latest designs. Along with affordable prices, we provide discounted delivery ...
(Date:12/25/2014)... 26, 2014 Recently, iFitDress.com, the popular online ... has announced its new selection of black one-shoulder cocktail ... sale now; they are available at discounted prices, up to ... promotion will last for three weeks only. You know, we ... who are interested in our new items can visit our ...
(Date:12/25/2014)... 26, 2014 Recently, Dylan Queen, a ... excitedly released its collection of discounted prom dresses, most ... a senior spokesman of the company, the promotion is ... promotion is to expand the UK market. , The ... different colors, lengths, and styles: A-line strapless, empire strapless ...
(Date:12/25/2014)... Los Angeles, CA (PRWEB) December 25, 2014 ... Blaise Dolcemaschio was created in honor of a true ... premiere at two film festivals including the 24 hours of ... Film Festival in Bangladesh. , Actress, screenwriter and ... and helped produce this film together with her husband, ...
Breaking Medicine News(10 mins):Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3
Other TagsOther Tags